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In studies of sexual mucosal transmission and early stages of
simian immunodeficiency virus (SIV) and HIV infections, productive
infection predominates in CD4 T cell populations, in both osten-
sibly resting and activated cells. The surprising ability of SIV and
HIV to replicate in resting cells in vivo, in contrast to propagation
of infection in vitro, suggested a model in which during the early
stages of infection these viruses exploit the greater availability of
resting cells to maintain unbroken chains of transmission from an
infected resting cell to another resting cell nearby. Because im-
mune activation in response to infection provides more activated
CD4 T cells, these viruses take advantage of the greater efficiency
of virus production and spread in activated cells for propagation
and dissemination of infection. In this article, we report the results
of experimental tests of this model, including visualization at the
light microscopic level and direct analysis of virus production by
cells in tissues. Analysis of tissues of rhesus macaques inoculated
intravaginally or i.v. with SIV supports the proposed roles of target
cell availability, susceptibility, and virus production by infected
resting and activated CD4 T cells in mucosal transmission and
early infection, and points to a potential role for topical anti-
inflammatory agents in moderating the initial propagation of
infection.
In previously reported studies of both the now globally predom-inant route of sexual transmission of HIV-1 to women (1), and the
animal model of intravaginal inoculation of simian immunodefi-
ciency virus (SIV) into rhesus macaques (2), the majority of
productively infected cells at the portal of entry and lymphatic
tissues (LTs) to which infection spreads were found to be CD4 T
cells. Similarly, in HIV-1 infection, from the acute to late stages of
infection, close to 90% of the HIV-1 RNA cells in the LT
reservoir where virus is produced were typed as CD4T cells (3, 4).
In the majority of these infected CD4 T cells in the early stages
of SIV infection, markers of cell activation and proliferation were
not detectable, and thus most of the productively infected popula-
tion in the very early stages of infection was apparently comprised
of resting CD4 T cells (3). This finding was quite surprising,
because both in vitro and in vivo HIV-1 was long thought to be
incapable of productively infecting quiescent T cells (5–8), and to
rely for propagation on productive infection of activated prolifer-
ating CD4 T cells (9–12). Moreover, the rapid depletion of CD4
T cells in gut-associated LTs and vagina in SIV infection has been
thought to be due to preferential replication of SIV in activated
CD4 T cells (13, 14). Nonetheless, recent reports of productive
infection of resting cells in ex vivo cultures of LTs and in patients
provide additional evidence that in vivo HIV can productively infect
resting CD4 T cells (15–17).
Why would productive SIV and HIV-1 infection be initially
found predominantly in resting CD4 T cells, and what role might
infection of these cells play in the early stages of infection? In the
target cell substrate availability model shown in Fig. 1, we propose
that it is initially mainly resting T cells that are infected after
intravaginal inoculation of SIV, simply because of the greater
density of resting T cells, compared with other susceptible cell types
such as dendritic cells (DCs) at the portal of entry. Whereas DCs
may be important in conveying virus across the mucosal barrier
(18), we reasoned that the CD4 T cell would quickly become the
major infected cell type because (i) CD4T cells outnumber other
potential target cell types in the female reproductive tract of
uninfected rhesus macaques (19) and, (ii) because the spatial
proximity of an infected CD4T cell to other CD4T cells in small
aggregates would facilitate propagation of infection in CD4 T
cells, compared with the more dispersed DCs and macrophages in
the submucosa. We further reasoned that more resting CD4 T
cells will be infected in the early stages of infection, because resting
CD4T cells will greatly outnumber the activated T cell population,
with a correspondingly greater likelihood of virus encountering and
infecting a resting T cell, until infection induces immune activation
both at the portal of entry and in the LTs to which infection
disseminates.
In this model, the proposed role of infection of resting CD4 T
cells is to produce sufficient virus to maintain the chain of trans-
mission during the early stages of infection. As infection progresses,
the immune activation associated with active viral replication would
provide larger numbers of activated CD4 T cells as potential
targets for infection. Whereas HIV and SIV can infect both
activated and resting CD4T cells, we have shown (3) that activated
CD4 T cells contain5-fold higher levels of SIV RNA than their
resting CD4 T cell counterparts, which is consistent with higher
levels of virus production. We therefore ascribe to infected acti-
vated CD4T cells the role of amplifiers that propagate and spread
infection more efficiently than resting cells, by producing more virus
to infect more cells at greater distances.
In this article, we report the results of experimental tests of the
predictions of the model: (i) that the proportions of susceptible cell
types initially infected should be related to the relative population
densities of each susceptible cell type; and, (ii) that changes in the
proportions of infected cells of each type should correspond to
changes in the population densities. We also describe a method to
directly visualize and measure, at the light microscopic level, virus
production by cells in tissues, and use this method to examine
another major prediction of the model, that infected activated
CD4 T cells produce more virions and could thus infect cells at
greater distances than infected resting CD4 T cells.
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Methods
Animals and Experimental SIV Infections. Cervical and LTs that were
reexamined and described in this report were from a previous study
(3) of female adult Indian rhesus macaques (Macaca mulatta) that
had been inoculated intravaginally with SIVmac251 and subsequently
killed. Tissues were collected and fixed as described (3). In longi-
tudinal studies of infection of LTs, adult female animals were
inoculated i.v. with SIVmac239. Sequential axillary lymph node
(LN) biopsies were obtained from anesthetized animals. Plasma
SIV RNA levels were determined as described previously (20). All
animal housing and care provided and research performed were in
conformance with the Guide for the Care and Use of Laboratory
Animals (21).
Immunohistochemical Staining (IHCS) and In Situ Hybridization (ISH).
IHCS and ISH, single- and double-label IHCS, and combined
ISHIHCS were performed as described (3).
Detection of Virions and Intracellular Viral RNA by ISHTyramide
Signal Amplification (TSA)Enzyme-Linked Fluorescence (ELF). To de-
tect virions embedded in agarose and in tissue sections, and viral
RNA in cells, sections were cut, deparaffinized, digested with
pepsin, washed and refixed in paraformaldehyde, and acetylated.
After hybridization to digoxigenin labeled virus-specific RNA
probes, washing and digestion with RNase A, bound probe was
detected by repeated cycles of TSA and incubation with streptavi-
din-alkaline phosphatase and ELF 97 substrate (Molecular
Probes), followed by extensive washes to reduce or eliminate
nonspecific precipitates of the ELF substrate. For combined ISH
IHC, after the ELF 97 substrate step, slides were incubated with
rabbit anti-Ki67 antibody, and then anti-rabbit IgG labeled with
Cy3.
For further details, see Supporting Methods, which is published as
supporting information on the PNAS web site.
Results and Discussion
Target Cell (Substrate) Availability and Proportions of Cell Types
Infected in Sexual Mucosal Transmission. The model shown in Fig. 1
predicts that the frequency of infection of different cell types at the
portal of entry and LTs to which infection spreads after intravaginal
exposure to SIV should be related to the likelihood of virus
encountering a susceptible cell and thus to the relative population
density of susceptible cell types in the tissues. To test this prediction,
we first determined the relationship between target cell availability
and proportion of infected cells in cervical and LTs in animals
exposed to SIV by intravaginal inoculation. We evaluated target cell
availability in archived tissues in which we had already determined
at day 7 that SIV RNA cells were confined to endocervix and that
at day 12 nearly 90% of the SIV RNA cells in endocervix and LN
were CD4 Ki67 HLA-DR resting T cells (3). Because the
remaining SIV RNA cells were CD4 Ki67 T cells, DCs, and
macrophages, these tissues provided an optimal test of the proposed
relationship between the frequency of productive infection of a
susceptible cell type and its relative population density.
We found that in endocervix CD4 T cells were 5-fold more
abundant than DCs and there were70 times as many Ki67CD4
T cells as CD4Ki67T cells (Table 1). CD4T cells were also four
times as abundant as macrophages, and both the macrophages and
DCs were dispersed through the submucosa, in contrast to the
CD4T cells that frequently clustered in small follicular aggregates
(data not shown). Thus, both the relative density and spatial
proximity of target cells would favor infection of predominantly
Ki67 CD4 T cells in these endocervical tissues, which is consis-
tent with our previous findings. Similarly, in the axillary LN to
which infection had spread 12 days after inoculation, Ki67CD4
T cells outnumbered Ki67 CD4 T cells, macrophages, and DCs
by an order of magnitude or more (Table 1). Thus, the demon-
stration in this report that Ki67CD4 T cells are the predominant
susceptible target cell in these tissues, combined with the previous
demonstration that the majority of SIV RNA cells in this LN were
Ki67CD4 T cells, satisfies this prediction of the model that
frequency of infection in susceptible cell populations will correlate
with the prevalence of target cell types.
Longitudinal Studies. The second major prediction of the model is
that the proportions of infected resting and activated T cells should
change as the proportion of activated CD4 T cells increases with
the immune activation that accompanies progressive infection. To
test this theory, we examined axillary LN biopsies 1 and 4 weeks
after i.v. inoculation of SIV. Consistent with the model, we found
that progressive immune activation altered the proportional rep-
resentation of activated and resting CD4 T cells in LTs, and thus
Table 1. Target cell availability
Cells per mm2
CD4T cells
CD68 macrophages S100 DCsKi67 Ki67
Endocervix* 413 6 104 90
Axillary LN* 13,598 363 1,388 1,067
Axillary LN† 13,699 83 1,698 1,125
*In rhesus macaque tissues before Intravaginal inoculation.
†In rhesus macaque tissues before i.v. inoculation.
Fig. 1. Target cell substrate availability and virus production by infected
resting and activated CD4 T cells in transmission and acute infection. Virus
that crosses the mucosal barrier and spreads to LTs can infect susceptible DCs,
macrophages, and both resting and activated CD4 cells at the portal of entry
and in LTs. Because the population of resting CD4 cells is larger than the other
cell types, most of the productively infected cells initially are resting CD4 T
cells. They propagate infection by infecting other nearby resting CD4 T cells.
Infected activated CD4 T cells produce more virions and transmit infection to
cells at greater distances than infected resting cells. Over time, infection-
related immune activation leads to an increasing proportion of activated
CD4 T cells in infected cell pool at the portal of entry and LTs, to which
infection is disseminated.









their availability for infection. In these experiments, we inoculated
animals i.v. with a large dose of SIV to maximally expose resting and
activated CD4 T cells, macrophages, and DCs in LTs to virus. At
the time of inoculation most of the potential target cells were
Ki67CD4 T cells (Table 1). Ki67CD4 T cells were approxi-
mately an order of magnitude more abundant than macrophages or
DCs, and more than two orders of magnitude more abundant than
activated Ki67 CD4 T cells. There was increased immune
activation at 4 weeks, compared with 1 week, with dramatic
increases in Ki67 B cells in lymphoid follicles and T cells (Fig. 2
A and B) and specifically, Ki67CD4 T cells, in the paracortex
(Fig. 2 C and D), which increased 3-fold from 1 to 4 weeks after
inoculation (Fig. 3A).
To evaluate changes in the size and proportion of Ki67 and
Ki67 SIV viral RNA CD4 T populations, we first determined
the proportion of different types of productively infected cells by
combining IHCS, using antibodies to identify CD4 T cells, mac-
rophages, or DCs, with ISH to determine the proportion of each cell
type that were SIV viral RNA. After i.v. inoculation,95% of the
SIV RNA cells in the LTs were CD4 T cells (data not shown),
which is equivalent to the proportion found after intravaginal
inoculation. To determine the proportion of productively infected
resting or activated cells in this population of infected CD4 cells,
we combined IHCS with antibodies to Ki67 and ISH, and then
counted the number of singly or doubly labeled cells per mm2 (Fig.
2 E and F). We found that the majority (80%) of SIV RNAT cells
at 1 week were Ki67, and 15% were activated CD4 T cells, which
is equivalent to the previously reported proportions of SIV RNA
resting and activated CD4 cells in LTs after intravaginal inocula-
tion. The proportion of SIV RNAKi67CD4 cells subsequently
increased 3-fold between weeks 1 and 4 (Fig. 3A), which is exactly
parallel to the increased proportion of activated T cells. This result
thus satisfies the second major prediction of the proposed model of
viral propagation in vivo at transmission and early stages of infec-
tion.
Substrate Exhaustion and Decreased Plasma Viremia. Two mecha-
nisms have been advanced to explain the decline in plasma levels of
HIV-1 and SIV typically observed in the acute stage of infection
after the initial peak in plasma viremia. There is evidence that
virus-specific cellular immune responses contribute to the decline
(22), but there is also theoretical (23) and experimental (13, 14)
support for the idea that exhaustion of activated CD4 T cells as
substrates for viral replication plays a major role. In the LTs of the
animals we studied, the frequency of activated CD4 T cells in LTs
increased 3-fold between weeks 1 and 4, even as levels of virus in
plasma fell (Fig. 3A). This result is inconsistent with the hypothesis
that plasma levels decline because of exhaustion of activated CD4
T cells as substrates for viral replication, at least in peripheral LTs.
Because we did not examine gut-associated LTs, it is possible that
depletion of activated CD4 T cells from this compartment could
contribute substantially to the decline in plasma viremia. Nonethe-
less, it is clear that global depletion of activated CD4 T cells in all
LTs cannot completely account for the observed down-regulation
of plasma viremia. Moreover, the parallel decreases in plasma SIV
RNA and infected CD4 T cells (Fig. 3B) is consistent with
elimination of productively infected cells in LTs by virus-specific
CD8 CTLs or other mechanism as the basis for the decrease in
plasma viremia.
Inherent Susceptibilities of Resting and Activated CD4 T Cells.
Although the results shown in Fig. 3A support the target cell
availability model, they also suggest that availability alone cannot
account for the predominance of infection in the activated CD4
T cell population at week 4. Even with a 3-fold increase in the
relative abundance of activated CD4 T cells at 4 weeks, there are
still many more resting CD4 T cells that could be infected if they
were equally susceptible to infection. Moreover, there are nearly 20
times fewer infected Ki67 CD4 T cells but only 2-fold fewer
infected Ki67 CD4 T cells at week 4, compared with week 1. We
interpret the shift in productive infection to the activated T cell
compartment as evidence of a cellular and lymphoid tissue milieu
(24) that enhances the susceptibility and ability of activated T cells
to replicate virus compared with resting cells.
Speculations That Only a Subset of Resting CD4 T Cells Can Support
Productive Infection and the Origins of Latently Infected Resting Cells.
The small fraction of resting CD4 T cells infected at both 1 and
4 weeks, relative to the sizes of the total resting CD4 T cell
population at these times, and the nearly 20-fold decrease between
weeks 1 and 4 in SIV RNAKi67T cells compared with the 2-fold
decrease in SIV RNA Ki67 T cells over this interval, also
requires explanation. One speculative possibility we propose here
is that only a small fraction of the resting population might actually
Fig. 2. Immune activation, availability, and infection of resting and activated
CD4 T cells. (A and B) There are increased numbers of Ki67 (brown stained) T
cells in the paracortex, and B cells in follicles in sections of LN at 4 weeks after i.v.
inoculation of SIV, compared with 1 week. (C and D) There are increased numbers
of Ki67 (blue gray nuclei) and CD4 T cells (red cytoplasm; arrows) at 4 weeks,
compared with 1 week. (E and F) There are more Ki67 (brown nuclei) and SIV
RNA (black silver grains; long arrows) cells at 4 weeks, compared with 1 week,
where most of the SIV RNA cells are Ki67 (short arrows).
Fig. 3. (A) Proportions of CD4 Ki67 or Ki67 T cells and SIV RNA Ki67 or
Ki67 cells. The proportions of SIV RNA Ki67 or Ki67 T cells were deter-
mined as described in the text and plotted as averages for the four animals
(solid lines and symbols) and individual animals (red dashed lines and open
symbols). (B) Changes in frequency of Ki67- and Ki67-infected T cells and
plasma SIV RNA level from weeks 1 to 4 after i.v. inoculation. Plasma SIV RNA
and frequency of SIV RNA cells were determined as described in Methods.
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be capable of supporting productive infection. For example, the
infectable population might be recently activated cells returning to
a resting state. Although they would be characterized as resting T
cells with the reagents currently available for immunophenotyping
in tissue sections, they may differ subtly from truly resting cells, e.g.,
as has been recently shown by Chun et al. (17), in the expression of
transcriptional regulatory and other genes, that enable them to
support productive infection. With the progressive immune activa-
tion that accompanies systemic SIV infection, there would be fewer
postactivated cells returning to this state, and thus, a smaller
population of resting cells to support productive infection. As the
initial population of productively infected resting CD4 T cells is
eliminated by immune or other mechanisms, the decreased avail-
ability of an infectable resting CD4 T cell population, and in-
creased relative frequency of the more susceptible activated CD4
T cells, would result in the observed greater proportional decrease
in the size of the viral RNAKi67 T cell population seen at week
4. The decreased numbers of infected resting cells observed at week
4 could also in part reflect conversion of the pool of initially
productively infected cells to a state of latent infection, a mecha-
nism in accord with recent ideas about the origins of the latently
infected resting CD4 T cell (25). Additionally or alternatively, the
initially infected resting cells could have slowly succumbed to the
cumulative cytopathic effects of viral replication, they could have
become activated, or they could have been eliminated by host
defenses.
Virus Production and Efficiency of Propagation and Spread of Infec-
tion. In the model shown in Fig. 1, infected resting T cells produce
fewer virions per cell but sustain infection in its earliest stages by
transmitting virus to resting T cells in close proximity. However,
infected activated T cells produce more virions per cell and thus
may transmit infection more efficiently, through multiplicity effects,
and at greater distances. We have previously used relative viral
RNA concentrations in infected cells (3) as a surrogate measure of
different levels of virus production, and also found higher concen-
trations of SIV RNA in activated cells, compared with resting cells,
in the lymph node biopsies of animals infected i.v. (data not shown).
To more rigorously quantify virus production in vivo by resting and
activated T cells, we developed an amplification method to visualize
virions at the light microscopic level to facilitate counting the
number of virions associated with cells in tissues. To visualize
virions, we detected viral RNA in them by ISH, and then amplified
the signal by TSA, followed by ELF, which generates a strong
fluorescent signal that is stable to quenching. We first showed that
we that we could visualize virions at the light microscopic level in
agarose sections containing predetermined concentrations of viri-
ons (Fig. 4), and then applied the method to estimate virus
production by resting and activated cells in tissue sections. We first
documented the specificity of the method in sections of axillary LN
12 days after intravaginal inoculation. We focused on this tissue
because, as described above, we had already shown that 85% of the
SIV RNA cells in this LN were CD4 cells, and, of these infected
CD4 T cells, 80% were small Ki67 T cells, whereas 15% were
large activated Ki67T cells. Fig. 5 illustrates the application of this
method and demonstrates several points. There are two large SIV
RNA cells in the field surrounded by virions concentrated within
2 cell diameters of the infected cell. At the upper left of the field,
there are smaller SIV RNA cells with relatively few virions visible
at the cell surface. The large activated cells are Ki67, whereas the
smaller SIV RNA cells with few virions are Ki67 (Inset). Neither
viral RNA nor virions were detectable by ISHTSAELF with an
SIV sense probe (Inset).
The axillary LN sample also provided an opportunity to test the
prediction of the model that activated T cells should transmit
infection to more cells, at greater distances, than infected resting T
cells. We had previously determined (26) that there was a statisti-
cally significant clustering of SIV RNA cells within approximately
one to two T cell diameters of each other in sections of this LN (26).
We now illustrate, in Fig. 5, the clustering of SIV RNA cells within
a few cell diameters of large activated T cells. The frequent
occurrence of small resting SIV RNA cells in pairs (see upper left
portion of Fig. 5) is consistent with close range transmission of
infection between resting cells shown in the model (Fig. 1).
Contributions of Resting and Activated CD4 T Cells to Virus Produc-
tion in Acute Infection. By using size to discriminate resting from
activated CD4 T cells, we estimated the numbers of virions
associated with small and large SIV RNA cells by focusing
through several planes at high magnification to clearly identify
particles. We counted particles over 100 cells and found that there
were, on average, five virions ( 2.9, range 1–17 virions) associated
with the small resting cells and 64 virions ( 38.7, range 19–220
virions) associated with large activated T cells. These are minimal
estimates, because there may have been some particles that could
not be distinguished from the background signal over the cellular
interior, mainly from intranuclear viral RNA, and thus would not
have been counted. Whereas cumulative virus production over time
cannot be determined from this type of analysis, the results nev-
ertheless document in this snap shot of infection a 12-fold greater
number of virions associated with activated compared to resting T
cells in tissues, which is consistent with the model shown in Fig. 1.
In previous studies (27) of the dynamics of HIV-1 infection in
LTs, two populations of mononuclear cells were originally identi-
fied that turned over with an apparent t1/21–2 days and a t1/214
days, respectively, after initiation of antiretroviral therapy. Subse-
quently, these two dynamic populations were shown to be activated
and resting CD4 T cells (3). Assuming similar t1/2 values in SIV
infection (28), we can estimate from the numbers of virions
associated with activated CD4 T cells and resting T cells that
cumulative virus production by activated T cells is only 1.5-fold
greater than resting CD4T cells. The relatively high per cell output
Fig. 4. Detection of virions by ISHTSAELF. Virions embedded in agarose
were detected in sections as described in Methods. The brightest and largest
viral particles in the figure are in the plane of focus. [Original magnifications:
600 (A) and 2,000 (B).]
Fig. 5. Detection by ISHTSAELF of SIV RNA in virions and in large Ki67 and
small Ki67 T cells in axillary LN. See text for explanation.









from resting cells, despite the small numbers of virions associated
with resting cells in ‘‘snapshots,’’ reflects the assumption, based on
a 14-day half-life, of production of virus over a longer period by
resting cells, which, presumably, are better able to survive the
cytopathic effects of replication and recognition by immune sur-
veillance because of lower levels of virus gene expression. Because
there are so many more infected resting cells, we can calculate virus
production from the weighted averages of population size and
relative virus production. This calculation leads to the conclusion
that the infected resting CD4 T cell population contributes
substantially to virus production in the very earliest stages of
infection (C.R., unpublished work).
Virion Production by Resting and Activated Cells and Sexual Mucosal
Transmission. We also found that after intravaginal inoculation of
SIV there are only a few viral particles at or close to the cell surface
of small resting T cells, whereas infected activated CD4 T cells are
surrounded by larger numbers of virions. We had previously shown
that almost all of the SIV RNA cells detected by ISH with
radiolabeled riboprobes in sections of cervix after intravaginal
inoculation of SIV were CD4 T cells (3), reflecting the greater
number of resting cells initially available. In reexamining these
tissues with ISHTSAELF, we again found that most of the SIV
RNA T cells in the submucosa (Fig. 6A) were small resting cells.
At higher magnification (Fig. 6 B and C), there are a few virions at
or near the cell surface of the small resting cells, whereas a cloud
of virions envelopes large activated T cells. This image captures the
proposed roles in the model of transmission at close distances by
resting cells and at greater distances by activated cells.
Mass-Action Model of Transmission and Establishment of Persistent
Infection. Expression of CD4 and coreceptors (29–33) define pop-
ulations of susceptible host cells that HIV and SIV can enter but
does not predict per se the relative proportions of susceptible cells
that will be productively infected in vivo or define mechanisms of
transmission and propagation of infection. We propose here and
provide evidence in support of what is essentially a mass-action
predator-prey model (34, 35) for the transmission of and initial
establishment of persistent SIV infection in LTs that accords to the
CD4 T cell the same preeminent role ascribed to this cell type in
HIV-1 infection (36). In this model, transmission and propagation
are related to the concentrations of infected cells, susceptible cells,
and virus. Continued propagation of infection, relative proportions
of productively infected cells of a particular type, and transmission
at close or longer range all will depend on the availability of
susceptible cellular substrates, the levels of virus production by
different cell types, and the proximity of infected cells to susceptible
cells; e.g., focal collections of CD4 T cells in the female repro-
ductive tract and the high density of CD4 T cells in LTs favor
propagation in CD4 T cells.
This mass-action model predicts that in the earliest stages of
infection, productive infection will predominate in the type of
susceptible cell at the highest concentration in the tissue. The
proportion of productively infected cells of a particular type at later
times will correspond to the representation of these cells in the
population at that time. The experimental data indicate that this
prediction is satisfied for the LTs studied. Within the first week of
infection, the majority of infected cells in LTs are resting CD4 T
cells. Between 1 and 4 weeks after i.v. inoculation of SIV, the
proportion of activated CD4 T cells increased 3-fold with a
parallel 3-fold increase in the proportion of infected activated
CD4 T cells. These findings are consistent with previous cross
sectional studies, that in the early stages of HIV-1 infection, a
substantial proportion (50%) of the HIV-1 RNA cells are
resting CD4T cells, whereas, at later stages, there is a proportional
increase in productively infected activated T cells that parallels
chronic immune activation (3). These findings collectively support
the idea that the relative availability of susceptible cellular sub-
strates is an important determinant of the relative proportions of
particular cell types that are productively infected and the contri-
bution that each cell type makes to the continued propagation of
infection at a particular stage of infection. The model can also
account for the previously reported finding that SIV RNA was
found mainly in macrophages in gut-associated LTs at a time
when CD4 T cells had been depleted (13), and for the shift of
infection to macrophages after the essentially quantitative acute
depletion of CD4 T cells in macaques infected with pathogenic
simianHIVs (37).
By visualizing virions, we have been able to directly estimate the
relative numbers of viral particles associated with resting and
activated cells and show that the surface of activated cells is
surrounded by 10 times as many virions as are seen for resting
cells. However, because resting cells turn over more slowly and far
outnumber infected activated cells in the very earliest stages of
infection, they could still contribute importantly to total virus
replication levels during early infection. They would thus fulfill their
proposed critical role in propagating infection by producing suffi-
cient virus to maintain the chain of transmission to nearby cells. As
the pool of activated CD4 T cells increases with immune activa-
tion, and is infected, this population becomes the major source of
virus production.
In the mass-action model, the greater production of virus and
diffusion of virions away from the productively infected activated T
cells should increase, through multiplicity effects, the efficiency and
likelihood of infecting another cell at greater distances. Both the
Fig. 6. Virus production by resting and activated T cells 12 days after
intravaginal inoculation of SIV. (A) Predominance of small over large SIV RNA
cells in ectocervical submucosa. (B and C) At higher magnification, virions are
evident at the surface and surrounding large activated T cells, in addition to
the bright yellow staining associated with intranuclear SIV RNA. In C, arrows
point to the small number of virions associated with small T cells. [Original
magnification: 600 (B), 800 (C), and 1,600 (Inset).]
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greater number of virions associated with infected activated T cells
documented here, and previously documented genotypic (38) and
spatial clustering of infected cells within two cell diameters (26) of
another infected cell, are in accord with and support this model. A
high local concentration of virus might also contribute to genetic
variability through superinfection and recombination in nearby
cells. Thus, the recently documented large number of recombinants
and multiple proviruses in cells (39) documented in HIV infection
need not arise from high systemic concentrations of virus, but
rather, may be generated through local multiplicity effects.
These studies have revealed vital roles for productive infection of
both resting and activated CD4T cells in intravaginal transmission
and establishment of systemic infection. We show in this report that
resting cells not only serve to maintain unbroken chains of trans-
mission but also likely contribute substantially to production of the
high levels of virus in early infection required for systemic dissem-
ination, a role for this cell population that heretofore has not been
appreciated. We document the even higher levels of virus produc-
tion by infected activated CD4 T cells that enable infection of
susceptible cells at greater distances from virus producing cells both
locally and throughout the LTs. The higher levels of virus produc-
tion by infected activated T cells could be a factor in the increased
transmission of HIV-1 in the setting of sexually transmitted dis-
eases, other infections, or other causes of preexisting inflammation,
e.g., induced by some microbicides (40–44). In addition to the
effects of inflammation on mucosal integrity, the increased num-
bers of activated cells that accompany inflammation, and the
important role that the infected activated T cell plays a role as an
amplifier to efficiently propagate and spread infection, suggests that
there could be a role for topical anti-inflammatory agents in
reducing the availability of these critical target cells, thereby re-
ducing sexual mucosal transmission andor moderating infection at
its earliest stages.
We thank Tammy Thompson and Colleen O’Neill for preparing the
manuscript, and Tim Leonard for the figures. This work was supported in
part with Federal funds from the National Institutes of Health under
National Cancer Institute Contract NO1-CO-12400 and Grants AI028246
and AI048484.
1. UNAIDSWHO (2002) UNAIDSWHO Report, December 2002 (UNAIDS
WHO, Geneva).
2. Miller, C. J., Alexander, N. J., Sutjipto, S., Lackner, A. A., Gettie, A. Hendricks,
A. G., Lowenstine, L. J., Jennings, M & Marx, P. A. (1989) J. Virol. 63,
4277–4284.
3. Zhang, Z.-Q., Schuler, T., Zupancic, M., Wietgrefe, S., Reimann, K. A.,
Reinhart, T. A., Rogan, M., Cavert, W., Miller, C. J., Veazey, D., et al. (1999)
Science 286, 1353–1357.
4. Schacker, T., Little, S., Connick, E., Gebhard, K., Zhang, Z.-Q., Krieger, J.,
Pryor, J., Havlir, D., Wong, J. K., Schooley, R. T., et al. (2001) J. Infect. Dis. 183,
555–562.
5. Stevenson, M., Stanwick, T. L., Dempsey, M. P. & Lamonica, C. A. (1990)
EMBO J. 9, 1551–1560.
6. Chou, C.-S., Ramilo, O. & Vitetta, E. S. (1997) Proc. Natl. Acad. Sci. USA 94,
1361–1365.
7. Tang, S., Patterson, B. & Levy, J. A. (1995) J. Virol. 69, 5659–5665.
8. Spina, C. A., Guatelli, J. C. & Richman, D. D. (1995) J. Virol. 69, 2977–2988.
9. Schnittman, S. M., Lane, H. C., Greenhouse, J., Justement, J. S., Baseler, M.
& Fauci, A. S. (1990) Proc. Natl. Acad. Sci. USA 87, 6058–6062.
10. Spina, A., Prince, H. E., Douglas D. & Richman J. (1997) Clin. Invest. 99,
1774–1785.
11. Bukrinsky, M. I., Stanwick, T. L., Dempsey, M. P. & Stevenson, M. (1991)
Science 254, 423–427.
12. Zack, J. A., Arrigo, S. J., Weitsman, S. R., Go, A. S., Haislip, A. & Chen, I. S. Y.
(1990) Cell 61, 213–222.
13. Veazey, R. S., DeMaria. M., Chalifoux, L. V., Shvetz, D. E., Pauley, D. R.,
Knight, H. L., Rosenzweig, M., Johnson, R. P., Desrosiers, R. C. & Lockner,
A. A. (1998) Science 280, 427–431.
14. Veazey, R. S., Marx, P. A. & Lackner, A. A. (2003) J. Infect. Dis. 187, 769–776.
15. Eckstein, D. A., Penn, M. L., Korin, Y. D., Scripture-Adams, D. D., Zack, J. A.,
Kreisberg, J. F., Roederer, M., Sherman, M. P., Chin, P. S. & Goldsmith, M. A.
(2001) Immunity 15, 671–682.
16. Blaak, H., van’t Wout, A. B., Brouwer, M., Hooibrink, B., Hovenkamp, E. &
Schuitemaker, H. (2000) Proc. Natl. Acad. Sci. USA 97, 1269–1274.
17. Chun, T.-W., Justement, J. S., Lempicki, R. A., Yang, J., Dennis, G., Jr.,
Hallahan, C. W., Sanford, C., Pandya, P., Liu, S., McLaughlin, M., et al. (2003)
Proc. Natl. Acad. Sci. USA 100, 1908–1913.
18. Pope, M. & Haase, A. T. (2003) Nat. Med. 9, 847–852.
19. Ma., Z., Lu¨, F. X., Torten, M. & Miller, C. J. (2001) J. Clin. Immunol. 100,
240–249.
20. Suryanarayana, K., Wiltrout, T. A., Vasquez, G. M., Hirsch, V. M. & Lifson,
J. D. (1998) AIDS Res. Hum. Retroviruses 14, 183–189.
21. Insitute for Laboratory Animal Research (1996) Guide for the Care and Use of
Laboratory Animals (Natl. Acad. Press, Washington, DC).
22. Koup, R. A., Safrit, J. T., Cao, Y., Andrews, C. A., McLeod, G., Borkowsky,
W., Farthing, C. & Ho, D. D. (1994) J. Virol. 68, 4650–4655.
23. Phillips, A. N. (1996) Science 271, 497–499.
24. Fauci, A. S. (1996) Nature 384, 529–534.
25. Persaud, D., Zhou, Y., Siliciano, J. M. & Siliciano, R. F. (2003) J. Virol. 77,
1659–1665.
26. Reilly, C., Schacker, T., Haase, A., Wietgrefe, S. & Krason, D. (2002) J. Am.
Stat. Assoc. 97, 943–954.
27. Cavert, W., Notermans, D. W., Staskus, K., Wietgrefe, S. W., Zupancic, M.,
Gebhard, K., Henry, K., Zhang, Z.-Q., Mills, R., McDade, H., et al. (1997)
Science 276, 960–964.
28. Nowak, M. A., Lloyd, A. L., Vasquez, G. M., Wiltrout, T. A., Wahl, L. M.,
Bischofberger, N., Williams, J., Kinter, A., Fauci, A. S., Hirsch, V. M. & Lifson,
J. D. J. Virol. (1997) 71, 7518–7525.
29. Paxton, W. A., Martin, S. R., Tse, D., O’Brien, T. R., Skurnick, J.,
VanDevanter, N. L., Padiau, N., Braun, J. F., Kotler, D. P., Wolingky, S. M.,
et al. (1996) Nat. Med. 2, 412–417.
30. Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R.,
MacDonald, M. E., Stuhlmann, H., Koup, R. A. & Landau, N. R. (1996) Cell
86, 367–377.
31. Dean, M., Carrington, M., Winkler, C., Huttley, G. A., Smith, M. W., Allikmets,
R., Goedert, J. J., Buchbinder, S. P., Vittinghoff, E., Gomberts, E., et al. (1996)
Science 273, 1856–1861.
32. Deng, H. K., Rong, L., Ellmeier, W., Choe, S., Unutmaz, D., Burkhard, M.,
DiMarzio, P., Marmon, S., Sutton, R. E., Hill, C. M., et al. (1996) Nature 381,
661–666.
33. Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy,
P. M. & Berger, E. A. (1996) Science 272, 1955–1958.
34. DeBoer, R. J. & Perelson, A. S. (1998) J. Theor. Biol. 190, 201–214.
35. Schwartz, E. J., Neumann, A. U., Teixiera, A. V., Bruggeman, L. A., Rappa-
port, J., Perelson, A. S. & Klotman, P. E. (2002) AIDS 16, 341–345.
36. Haase, A. T. (1999) Annu. Rev. Immunol. 17, 625–656.
37. Igarashi, T., Brown, C. R., Endo, Y., Buckler-White, A., Plishka, R., Bischof-
berger, N., Hirsch, V. & Martin, M. A. (2001) Proc. Natl. Acad. Sci. USA 98,
658–663.
38. Reinhart, T. A., Rogan, M. J., Amedee, A. M., Murphey-Corb, M., Rausch,
D. M., Eiden, L. E. & Haase, A. T. (1998) J. Virol. 72, 113–120.
39. Jung, A., Maier, R., Vartanian, J. P., Bocharov, G., Jung, V., Fischer, U.,
Meese, E., Wain-Hobson, S. & Meyerhans, A. (2002) Nature 418, 144.
40. Martin, H. L., Richardson, B. A., Nyange, P. M., Lavreys, L., Hillier, S. L.,
Chohan, B., Mandaliya, K., Ndinya-Achola, J. O., Bwayo, J., Kreiss, J., et al.
(1999) J. Infect. Dis. 180, 1863–1868.
41. Sweankambo, N., Gray, R. H., Wawer, M. J., Paxton, L., McNairn, D.,
Wabwire-Mangen, F., Serwadda, D., Chuanjun, L., Kiwanuka, N., Hiller, S. L.,
et al. (1997) Lancet 350, 546–550.
42. Cohn, M. A., Frankel, S. S., Rugpao, S., Young, M. A., Willett, G.,
Tovanabutra, S., Khamboonruang, C., VanCott, T., Bhoopat, L., Barrick, S., et
al. (2001) J. Infect. Dis. 184, 410–417.
43. Moss, G. B., Clemetson, D., D’Costa, L., Plummer, F. A., Ndinya-Achola, J. O.,
Reilly, M., Holmes, K. K., Piot, P., Maitha, G. M., Hillier, S. L., et al. (1991)
J. Infect. Dis. 164, 588–591.
44. Van Damme, L., Ramjee, G., Alary, M., Voylsteke, B., Chandeying, V., Rees,
H., Sirivongrangson, P., Mukenge-Tshibaka, L., Ettienge-Traore, V., Uahe-
owitchai, C., et al. (2002) Lancet 360, 971–977.









Roles of substrate availability and infection 
of resting and activated CD4+ T cells in 
transmission and acute simian 
immunodeficiency virus infection 
Supporting Methods 
Animals and Experimental SIV Infections. Cervical and LTs that were reexamined and described 
in this report were from a previous study (1) of 14 female adult Indian rhesus macaques (Macaca 
mulatta) that had been atraumatically inoculated intravaginally with 1 ml of tissue culture 
supernatant containing 10
5
 tissue culture 50% infective dose of an uncloned biological dual 
tropic isolate of SIVmac251. The animals received a second 1-ml dose 4 h later. This dose infects 
100% of the animals exposed to SIV by this route. At 1, 3, 5, 7, and 12 days thereafter, the 
animals were killed and tissues were collected and fixed in formalin and Streck’s tissue fixative, 
as described (1). In longitudinal studies of direct infection of LTs, four adult female SIV- and 
simian retrovirus-negative animals received an i.v. infusion of 2 × 10
4
 median 50% effective 
dose of SIVmac239, generously provided by R. Desrosiers (New England National Primate 
Research Center, Southborough, MA). Blood samples were obtained from the femoral veins 
alternating between the left and right, under anesthesia, with Telazol given intramuscularly at 3 
mg per kg of body weight. For sequential LN biopsies (left axillary, right axillary), anesthesia 
was induced with Telazol (6 mg/kg intramuscularly) and maintained with 1.5-2% isoflurane 
administered through an endotracheal tube. Plasma SIV RNA levels were determined by using a 
real-time RT PCR method, essentially as described (2). All animal housing and care provided 
and research performed were in conformance with the Guide for the Care and Use of Laboratory 
Animals (3). 
IHCS and ISH. IHCS and ISH, single- and double-label IHCS, and combined ISH/IHCS were 
performed as described (1). In brief, for double-label IHCS of CD4
+
 T cells, sections were 
microwaved for 4 min in 1 mM EDTA for antigen retrieval, and were then incubated at room 
temperature for 30 min with a 1:5 dilution of mouse anti-human CD4 (NCL-CD4-IF6; 
Novocastra Laboratories, Newcastle, U.K.). Binding of antibody was detected with alkaline 
phosphatase antialkaline phosphatase by using Vector red (SK5100, Vector Laboratories, 
Burlingame, CA). After blocking (DAKO doublestain kit K1395), the sections were incubated at 
room temperature for 30 min with a 1:40 dilution of anti-Ki67 rabbit polyclonal antibody 
(DAKO, K4009, Hamburg, Germany) followed by staining with the Dako EnVision+ AP kit. 
Ki67 was visualized with alkaline phosphatase antialkaline phosphatase and Vector SG. For 
combined ISH/IHCS, deparaffinized sections were microwaved and CD4 was visualized by 
IHCS with the DAKO Envision+ Peroxidase kit, mouse anti-human CD4, and diaminobenzidine. 
After washing and permeabilization by treating the sections with HCl, digitonin, and proteinase 
K, the sections were acetylated and hybridized to 
35
S-labeled SIV-specific riboprobes. After 
washing and digestion with ribonucleases, sections were coated with nuclear track emulsion, 
exposed, developed, and counterstained with hematoxylin. 
ISH/TSA/ELF Detection of Virions and Intracellular Viral RNA. To validate a method for 
detection of virion-associated viral RNA described in this report, agarose sections of virions 
were prepared from stocks of HIV containing known concentrations of virus, which were 
redetermined based on GFP labeling of the virions (generously provided by X. Wu, University of 
Alabama at Birmingham, Birmingham). As described below, the GFP label is not detectable after 
the amplification procedures. Stocks were diluted in SM buffer of Tris, NaCl, and MgSO4 
buffered 1.5% in agarose and fixed in 1% paraformaldehyde in an Eppendorf tube. The tube was 
placed on ice for 2 h. to solidify the agarose. The agarose pellet was subsequently removed from 
the tube, dehydrated through graded ethanols, xylene, and embedded in paraffin. Six- m 
sections were cut, placed on silanized slides, and baked at 60°C for 60 min. After 
deparaffinization in xylene, slides were placed in ethanol with 0.5% H2O2 for 20 min and were 
rehydrated through graded ethanols. At this point, virions are no longer fluorescent, because the 
pretreatments denature the GFP label used to determine virion particle concentrations. To detect 
virions and viral RNA in cells in tissue sections, LNs, cervixes, and vaginas from SIV-infected 
macaques were fixed for 4 h. in 4% paraformaldehyde, dehydrated through graded ethanols, 
xylene, and were paraffin-embedded. Six- m sections were cut, placed on silanized slides, and 
baked at 60°C for 60 min. After deparaffinization in xylene, slides were placed in ethanol with 
0.5% H2O2 for 20 min and were rehydrated through graded ethanols. Slides were incubated in 
0.2 M HCl for 10 min, digested with pepsin (50  g/ml for virions or 150  g/ml for tissue 
sections) in 20 mM HCl for 10 (virions) or 15 min (tissue sections) at room temperature. After 
washing in PBS and fixation in 2% paraformaldehyde for 15 min, the slides were acetylated for 
15 min with 0.25% acetic anhydride in 0.1 M triethanolamine, pH 8. After dehydration through 
graded ethanols, digoxigenin-labeled virus-specific RNA probes were hybridized overnight at 
45°C in 50% formamide/5% dextran sulfate/1 mM EDTA/20 mM Hepes (pH 7.5)/0.1% SDS/50 
 g/ml yeast RNA. After washing in 5 × SSC at 45°C, in 2 × SSC 50% formamide at 50°C, and 
0.1 M Tris•HCl (pH 7.5)/0.15M NaCl at 37°C, slides were digested for 60 min at 37°C with 30  
g/ml RNase A in Tris•NaCl buffer and were washed in 2 × SSC at 37°C for 15 min. Bound 
digoxigenin RNA probe was detected by TSA. Slides were placed in a blocking solution for 1 h. 
(Tris NaCl blocking buffer solution, 2% sheep serum, and 25 mM NH4SCN) and were then 
incubated overnight at 4°C with a 1:1,500 dilution of anti-digoxygenin peroxidase conjugate 
(Roche) in TNB, sheep serum and 25 mM NH4SCN. After washing four times in TNT (Tris, 
NaCl, and Tween 20), the slides were incubated for 7 min at 26°C with a solution of biotinyl 
tyramine in amplification diluent (Perkin--Elmer) containing 25% Dextran 500 (Pharmacia) to 
reduce the diffusion of reacted tyramine. After washing three times in TNT, avidin biotinyl-
peroxidase (ABC Elite, Vector Laboratories) diluted in TNB was added to the slides for 30 min. 
Washing three times in TNT completes one round of amplification. The amplification step was 
repeated with biotinyl tyramine, ABC reagent, and biotinyl tyramine. The slides were then 
incubated for 30 min with 1:60-diluted streptavidin-alkaline phosphatase in blocking buffer 
(Molecular Probes) and were washed three times for 15 min in wash buffer. Slides were 
incubated with ELF 97 substrate (Molecular Probes), stained with Hoechst 33342, were washed 
in TNT for 1-3 days to reduce or eliminate nonspecific precipitates of the ELF substrate, and 
were mounted in Aquapolymount (Polysciences). For combined ISH/IHC, following the ELF 97 
substrate step, the slides are incubated 1 min in citrate buffer at 95°C, blocked, incubated with 
rabbit anti-Ki67 antibody, washed, and incubated with anti-rabbit IgG labeled with Cy3. 
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